Skip to content
OpenCapital
Get started

Lexicon Pharmaceuticals LXRX Payment, Tax Withholding, Share-Based Payment Arrangement

Payment, Tax Withholding, Share-Based Payment Arrangement at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+273%
Enterprise value$976.73M+219%
P/S14.2×+5.7×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's payment, tax withholding, share-based payment arrangement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's payment, tax withholding, share-based payment arrangement?
Lexicon Pharmaceuticals (LXRX) reported payment, tax withholding, share-based payment arrangement of $2.84M in Q1 2026.
How has Lexicon Pharmaceuticals's payment, tax withholding, share-based payment arrangement changed year-over-year?
Lexicon Pharmaceuticals's payment, tax withholding, share-based payment arrangement increased by 397.0% year-over-year, from $572K to $2.84M.
What does payment, tax withholding, share-based payment arrangement mean?
Represents cash outflows made by the company to tax authorities on behalf of employees to satisfy statutory tax withholding requirements related to share-based compensation awards. This reflects the cash impact of settling equity-based incentives.